Goodwin is actively seeking Associate attorneys to join its Intellectual Property (“IP”) Litigation team on both the East and West coast. Goodwin is looking for highly qualified, motivated, and team-oriented junior and mid-level IP litigation associates who focus on technology, life sciences, or both. Associates may join any of Goodwin’s…
Goodwin is actively seeking Science Advisors to join its Intellectual Property (IP) Litigation group. IP litigation requires both an understanding of the law and a firm handle on the technical aspects of the patents at issue, especially when the patents cover complex technologies including those in the pharmaceutical space. “Science…
Goodwin and the Big Molecule Watch team are looking forward to participating in the 37th Annual JP Morgan Healthcare Conference, bringing together industry leaders from across the country. If you are at the conference in San Francisco, we hope you will join the team today, January 9, 2019 for our…
Goodwin’s Willy Jay is speaking on a panel this week at the Annual Meeting of the Association for Accessible Medicines, formerly known as the Generic Pharmaceutical Association, Access 2018. Mr. Jay’s panel focuses on issues relating to closing the legal loopholes blocking access to generics and biosimilars. AAM states that…
Goodwin and the Big Molecule Watch team are looking forward to participating in the 36th Annual J.P. Morgan Healthcare Conference, bringing together industry leaders from across the country. If you are planning to attend the conference in San Francisco, we hope you will join the team next Wednesday, January 10,…
Goodwin’s Intellectual Property and Life Sciences teams won three awards, and were shortlisted in 10 categories for over 10 awards, at the 2017 LMG Life Sciences Awards hosted in New York City on September 13. The awards recognized and honored the leading attorneys, firms and in-house counsel teams who have…
We post frequently about IPRs here on the blog, because they are an efficient and relatively quick way to get a decision on validity of the patents that cover drugs, biologic or otherwise. In Merck & Cie v. Gnosis S.p.A., the Supreme Court denied certiorari after the Federal Circuit affirmed that the standard…